<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>EMT reversal &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/emt-reversal/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 22 Sep 2025 14:03:04 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>EMT reversal &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Bispecific Affitoxin Targets HPV, Enhances Cervical Cancer Therapy</title>
		<link>https://bioengineer.org/bispecific-affitoxin-targets-hpv-enhances-cervical-cancer-therapy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 22 Sep 2025 14:02:47 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Bispecific affitoxin]]></category>
		<category><![CDATA[E7 oncoprotein]]></category>
		<category><![CDATA[EMT reversal]]></category>
		<category><![CDATA[HPV cervical cancer]]></category>
		<category><![CDATA[targeted cancer therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/bispecific-affitoxin-targets-hpv-enhances-cervical-cancer-therapy/</guid>

					<description><![CDATA[In recent years, the urgency to combat human papillomavirus (HPV) related cervical cancer has led scientists to explore innovative therapeutic avenues. One remarkable study published in the Journal of Translational Medicine introduces a groundbreaking bispecific affitoxin that demonstrates unparalleled promise in targeting E7 proteins from HPV types 16 and 18. These types are notorious for [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">271063</post-id>	</item>
	</channel>
</rss>
